Should I Buy TEVA? TEVA 2026 Analysis

Should You Buy Teva Pharmaceutical Industries Limited.. (TEVA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

31.480

1 Day change

-3.32%

52 Week Range

37.340

Analysis Updated At

2026/06/19

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Teva Pharmaceutical Industries Limited (TEVA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock has seen a recent price decline, and while analysts maintain positive ratings with a higher price target, insider selling and lack of immediate trading signals suggest caution. Waiting for further clarity on upcoming earnings and catalysts may be prudent.

Technical Analysis

The MACD histogram is negative and expanding, indicating bearish momentum. RSI is at 25.325, suggesting the stock is oversold but not yet signaling a reversal. The stock is trading near its S1 support level (31.494), with no clear breakout or reversal signals.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts maintain strong buy ratings with price targets ranging from $40 to $
Submission of an NDA for ecopipam to treat pediatric Tourette syndrome, supported by positive phase 3 trial data.
Strong growth in branded drug sales and biosimilars business over the past year.

Neutral/Negative Catalysts

Insider selling has increased significantly (764.83%) over the last month.
Recent price decline (-3.32% in regular market and -0.41% post-market).
Delay in clinical trial completion for vitiligo treatment, potentially impacting investor sentiment.

Financial Performance

No financial data available for the latest quarter. Upcoming Q2 2026 earnings report on July 29, 2026, will provide more clarity.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are positive on TEVA, with multiple firms raising price targets to $40-$50 and highlighting strong performance in branded drugs, pipeline expansion, and strategic acquisitions. However, recent price weakness is attributed to macro factors and perceived delays in clinical trials.

11 Analyst Rating

Wall Street analysts forecast TEVA stock price to rise

10 Buy

1 Hold

0 Sell

Strong Buy

Current: 32.560

Low

Averages

35.71

High

Current: 32.560

Low

Averages

35.71

High

Jefferies

Dennis Ding

Buy

maintain

$40

AI Analysis

2026-06-18

New

Reason

Jefferies

Dennis Ding

Price Target

$40

AI Analysis

2026-06-18

New

maintain

Buy

Reason

Noting that Teva has underperformed the last two weeks, Jefferies analyst Dennis Ding explained that a "big part of the weakness is due to macro," but also says it may potentially be due to how investors perceived management comments on vitiligo at a recent conference as well as a clinicaltrials.gov update showing vitiligo's primary completion is now September instead of May. However, after having caught up with the investor relations team, who noted there's no change to internal confidence on vitiligo and reiterated the data will be right after July 4 weekend, the firm continues to like shares after the pullback and keeps a Buy rating and $40 price target on Teva.

Barclays

NULL

Overweight

maintain

$38 -> $40

2026-05-06

Reason

Barclays

Price Target

$38 -> $40

2026-05-06

maintain

NULL

Overweight

Reason

Barclays raised the firm's price target on Teva to $40 from $38 and keeps an Overweight rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TEVA

Unlock Now

TEVA Should I Buy

TEVA Should I Buy

Should You Buy Teva Pharmaceutical Industries Limited.. (TEVA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch